Figure 3.

Baseline immune cell frequencies predict antitumor activity and irAEs on afatinib and pembrolizumab. Flow cytometric analysis from patients with disease control more than 6 months or PR to treatment (R) (blue) versus patients with PD or PFS less than 6 months (NR) (red). (A) Line graphs revealing frequencies of CD8⁺ effector memory T-cells, naive CD8⁺ T-cells, and CD8⁺ central memory T-cells at baseline and day 1 of cycle 3. Median values with 75th and 25th percentile whiskers. A mixed effects model was used to calculate the repeated measures p value. (B) Receiver operator characteristic curve for baseline CD8⁺ effector memory T-cells, naive CD8⁺ T-cells, and CD8⁺ central memory T-cells, R versus NR. Corresponding AUC are revealed. (C) Representative flow cytometry contour plots representing data used to construct line graph and receiver operator characteristic curves are revealed. Note: All patients with disease control more than 6 months or PR to treatment also experienced an irAE. Nonresponders did not experience irAEs. AUC, area under the curve; CM, central memory; EM, effector memory; irAE, immune-related adverse event; PFS, progression-free survival.